Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 3:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 218 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Index Event Clear all
Not yet recruiting Not applicable Interventional

Evaluating the Impact of Digital Behavioral Interventions to Address Insomnia and Depression in Breast Cancer Survivors Using an Adaptive Design

NCT07721064
View directory record Official record
Conditions
Insomnia, Depression
Interventions
Digital Insomnia Program, Digital Mental Health Program, Psychoeducation
Behavioral
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older · Female only
Enrollment
747 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 23, 2026, 3:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Validation of a Novel Device for Screening Patients With Symptoms of Obstructive Sleep Apnea

NCT04121923
View directory record Official record
Conditions
Sleep Apnea, Obstructive
Interventions
Belun Ring Pulse Oximeter
Device
Lead sponsor
Belun Technology Company Limited
Other
Eligibility
18 Years to 90 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 23, 2026, 3:43 PM EDT
Recruiting Phase 2 Interventional

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

NCT06859424
View directory record Official record
Conditions
AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category), MDS (Myelodysplastic Syndrome), CML (Chronic Myelogenous Leukemia), CLL (Chronic Lymphocytic Leukemia), Prolymphocyctic Leukemia, Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasm (MPN), Lymphoma, Myelofibrosis
Interventions
Conditioning Regimen A, Conditioning Regimen B, Conditioning Regimen C, Conditioning Regimen D, Conditioning Regimen E, Hematopoietic Cell Transplantation, PTCy (50 mg/kg D3, D4), PTCy (25 mg/kg D3, D4), Post-transplant Tacrolimus, Post-transplant Mycophenolate mofetil, Post-transplant Abatacept, Post-transplant Ruxolitinib, Supportive Care: Growth Factors, Supportive Care: Blood Products, Supportive Care: Infection Prophylaxis, Supportive Care: Intravenous immune globulin (IVIG), Supportive Care: Seizure prophylaxis, Supportive Care: Monitoring and management of CRS, Supportive Care: Prophylaxis against infections, Supportive Care: Prophylaxis against infections, Supportive Care: Lipid elevations, Study treatment compliance, Prohibited Concomitant Therapy, Permitted Concomitant Therapy
Drug · Procedure · Other
Lead sponsor
Center for International Blood and Marrow Transplant Research
Network
Eligibility
18 Years to 66 Years
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
13
States / cities
Birmingham, Alabama • Duarte, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 23, 2026, 3:43 PM EDT
Recruiting Not applicable Interventional

Fluid Guided Heart Failure Treatment at the Cleveland Clinic

NCT07205120
View directory record Official record
Conditions
Heart Failure
Interventions
Heart Failure Management Intervention
Device
Lead sponsor
Bodyport Inc.
Industry
Eligibility
21 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 23, 2026, 3:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Detection of Sleep Stages and Arousals Using Neural Network Classifiers

NCT07136272
View directory record Official record
Conditions
Sleep Disordered Breathing (SDB), Sleep Apnea
Interventions
SSAM, Polysomnography, EnsoSleep
Device · Diagnostic Test
Lead sponsor
Pathway Medtech, LLC.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
3
States / cities
Burlingame, California • Irvine, California • La Jolla, California
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 23, 2026, 3:43 PM EDT
Completed Not applicable Interventional Results available

Feasibility Trial of a Single Session of Crisis Response Planning for Youth at High Risk for Suicide

NCT06164106
View directory record Official record
Conditions
Suicide Prevention
Interventions
Virtual Crisis Response Planning, In-Person Crisis Response Planning, Crisis Risk Counseling
Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
14 Years to 18 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 23, 2026, 3:43 PM EDT
Completed Phase 3 Interventional Results available

Cardiovascular Inflammation Reduction Trial

NCT01594333
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Methotrexate, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
4,786 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
404
States / cities
Birmingham, Alabama • Fort Payne, Alabama • Guntersville, Alabama + 296 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2020 · Synced Oct 23, 2026, 3:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Inhibitory Control Training in Eating Behaviors

NCT03599115
View directory record Official record
Conditions
Overweight and Obesity
Interventions
Inhibitory Control Training
Behavioral
Lead sponsor
Brigham Young University
Other
Eligibility
18 Years to 45 Years
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Provo, Utah
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Oct 23, 2026, 3:43 PM EDT
Terminated Phase 3 Interventional Results available

Niacin Plus Statin to Prevent Vascular Events

NCT00120289
View directory record Official record
Conditions
Cardiovascular Diseases, Heart Diseases, Cerebrovascular Accident, Coronary Disease, Atherosclerosis, Myocardial Infarction
Interventions
Extended release niacin, Simvastatin
Drug
Lead sponsor
Axio Research. LLC
Industry
Eligibility
45 Years and older
Enrollment
3,414 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
68
States / cities
Birmingham, Alabama • Hoover, Alabama • Pheonix, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2016 · Synced Oct 23, 2026, 3:43 PM EDT
Active, not recruiting No phase listed Observational

A Study to Assess Long-term Outcomes of Myocarditis Following Administration of COVID-19 mRNA Vaccine (SPIKEVAX)

NCT06189053
View directory record Official record
Conditions
Myocarditis
Interventions
Not listed
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
Not listed
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 1, 2025 · Synced Oct 23, 2026, 3:43 PM EDT
Recruiting Early Phase 1 Interventional

A Phase 0/1 Study of cDNA for TP53, Checkpoint Inhibition and Radiation in Children With Recurrent, Progressive or Refractory CNS Malignancies.

NCT07017816
View directory record Official record
Conditions
CNS Malignancies, Medulloblastoma Recurrent, ATRT Recurrent, Pineoblastoma, Embryonal Neoplasm, Ependymoma Recurrent, High Grade Gliomas
Interventions
SGT-53, hypofractionated radiotherapy with immunotherapy, Nivolumab
Drug · Radiation
Lead sponsor
Children's National Research Institute
Other
Eligibility
3 Years to 21 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 23, 2026, 3:43 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Metabolism and Sleep Apnea Treatment

NCT05539716
View directory record Official record
Conditions
Obstructive Sleep Apnea, Fat Disorder
Interventions
PAP Therapy, Lifestyle Counseling Intervention
Device · Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 23, 2026, 3:43 PM EDT
Completed Not applicable Interventional

Phenotyping Mechanistic Pathways for Adverse Health Outcomes in Sleep Apnea

NCT04575740
View directory record Official record
Conditions
Sleep Apnea
Interventions
PAP
Device
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
21 Years to 80 Years
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 23, 2026, 3:43 PM EDT
Completed No phase listed Observational Results available

Surveillance and Alert-based Multiparameter Monitoring to Reduce Worsening Heart Failure Events

NCT04882449
View directory record Official record
Conditions
Heart Failure
Interventions
Bodyport Cardiac Scale
Device
Lead sponsor
Bodyport Inc.
Industry
Eligibility
18 Years and older
Enrollment
329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
8
States / cities
Boynton Beach, Florida • Panama City, Florida • Gainesville, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Oct 23, 2026, 3:43 PM EDT
Completed Not applicable Interventional

Effects of Upper Airway Muscle Training on OSA

NCT02502942
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Upper Airway Muscle Exercise, Sham Exercise
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 79 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 23, 2026, 3:43 PM EDT
Completed Phase 3 Interventional

Warfarin and Antiplatelet Therapy in Chronic Heart Failure

NCT00007683
View directory record Official record
Conditions
Heart Failure
Interventions
Warfarin titrated to an INR of 2.5-3.0, Aspirin, Clopidogrel 75
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
1,587 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
79
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 76 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2011 · Synced Oct 23, 2026, 3:43 PM EDT
Completed Phase 2 Interventional Results available

Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

NCT00481195
View directory record Official record
Conditions
Bipolar I Depression
Interventions
Armodafinil, Placebo
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 65 Years
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
42
States / cities
Birmingham, Alabama • Escondido, California • Lafayette, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2013 · Synced Oct 23, 2026, 3:43 PM EDT
Completed No phase listed Observational

Ruxolitinib for Polycythemia Vera in Patients Resistant to or Intolerant of Hydroxyurea.

NCT05421104
View directory record Official record
Conditions
Polycythemia Vera (PV)
Interventions
Ruxolitinib
Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
1,576 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 5, 2022 · Synced Oct 23, 2026, 3:43 PM EDT
Completed No phase listed Observational

Pfizer-BioNTech COVID-19 Vaccine Effectiveness Study - Kaiser Permanente Southern California

NCT04848584
View directory record Official record
Conditions
COVID-19
Interventions
Primary Exposure Status of Pfizer-BioNTech COVID-19 Vaccine, BNT162b2 BA.4/5 bivalent, XBB.1.5-adapted vaccinated
Biological
Lead sponsor
Pfizer
Industry
Eligibility
0 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Oct 23, 2026, 3:43 PM EDT
Recruiting Phase 2Phase 3 Interventional

Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

NCT03013998
View directory record Official record
Conditions
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Interventions
Samalizumab (BAML-16-001-S1), BI 836858 (BAML-16-001-S2), Laboratory Biomarker Analysis, Daunorubicin (BAML-16-001-S1), Cytarabine (BAML-16-001-S1), Azacitidine (BAML-16-001-S2), AG-221 (BAML-16-001-S3), Azacitidine (BAML-16-001-S3), Entospletinib (BAML-16-001-S4), Azacitidine (BAML-16-001-S4), Entospletinib (BAML-16-001-S5), Decitabine (BAML-16-001-S5), Entospletinib (BAML-16-001-S6), Daunorubicin (BAML-16-001-S6), Cytarabine (BAML-16-001-S6), Pevonedistat (BAML-16-001-S9), Azacitidine (BAML-16-001-S9), AG-120 (BAML-16-001-S16), Azacitidine (BAML-16-001-S16), Gilteritinib (BAML-16-001-S8 Group 1), Decitabine (BAML-16-001-S8 Group 1), AZD5153 (BAML-16-001-S10), Venetoclax (BAML-16-001-S10), TP-0903 (BAML-16-001-S14), Decitabine (BAML-16-001-S14), Decitabine (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S8 Group 2), AZD5991 (BAML-16-001-S18), Azacitidine (BAML-16-001-S18), SNDX-5613 (BAML-16-001-S17), Azacitidine (BAML-16-001-S17), Venetoclax (BAML-16-001-S17), Gilteritinib (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S12 Arm A), Azacitidine (BAML-16-001-S12 Arm A), Venetoclax (BAML-16-001-S12 Arm B), Azacitidine (BAML-16-001-S12 Arm B), ZE46-0134 (BAML-16-001-S21 Group 1), ficlatuzumab (BAML-16-001-S24), Azacitidine (BAML-16-001-S24), Venetoclax (BAML-16-001-S24), ZE46-0134 (BAML-16-001-S21 Group 2), Bleximenib (BAML-16-001-S25/HO181), Cytarabine (BAML-16-001-S25/HO181), Daunorubicin or Idarubicin (BAML-16-001-S25/HO181), Placebo (BAML-16-001-S25/HO181), Revumenib (BAML-16-001-S26/HO177), Placebo (BAML-16-001-S26/HO177)
Biological · Other · Drug
Lead sponsor
Beat AML, LLC
Other
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2032
U.S. locations
31
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 23, 2026, 3:43 PM EDT
Completed Phase 4 Interventional Results available

Safety and Cardiovascular Efficacy of Hydralazine and Isosorbide Dinitrate in Dialysis-Dependent ESRD

NCT02228408
View directory record Official record
Conditions
Chronic Hemodialysis (ESRD)
Interventions
Hydralazine/Isorsorbide Dinitrate, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Oct 23, 2026, 3:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Prospective Cohort Study of Accelerated Resolution Therapy (ART) for Treatment of Military Psychological Trauma

NCT02030522
View directory record Official record
Conditions
Post-traumatic Stress Disorder (PTSD)
Interventions
Accelerated Resolution Therapy (ART)
Behavioral
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
8
States / cities
Clearwater, Florida • Holiday, Florida • Jupiter, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2020 · Synced Oct 23, 2026, 3:43 PM EDT
Completed Phase 2 Interventional Results available

The Sleep, Liver Evaluation and Effective Pressure Study

NCT01482065
View directory record Official record
Conditions
Non Alcoholic Fatty Liver Disease, Obstructive Sleep Apnea
Interventions
CPAP (ResMed S9 autoset CPAP)
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 4, 2017 · Synced Oct 23, 2026, 3:43 PM EDT
Recruiting Not applicable Interventional

Effect of Text Message Reminders on M-ISI Score After Prostate Surgery

NCT07071207
View directory record Official record
Conditions
Incontinence, Urinary Stress, Prostate Cancer, Benign Prostate Hyperplasia
Interventions
Text message reminders
Behavioral
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older · Male only
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 23, 2026, 3:43 PM EDT